Drug Profile


Alternative Names: Byvalson; Valsartan/nebivolol

Latest Information Update: 13 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Forest Laboratories
  • Developer Allergan
  • Class Antihypertensives; Benzopyrans; Ethanolamines; Ischaemic heart disorder therapies; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Beta 1 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Essential hypertension

Most Recent Events

  • 07 Jun 2016 Registered for Essential hypertension in USA (PO) (First global approval)
  • 07 Jun 2016 The US approved label of nebivolol/valsartan tablets carries a black box warning
  • 22 Feb 2016 Allergan announces intention to submit NDA to US FDA in the first half of 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top